Bristol takes aim at three more hep C niches with Daklinza

In the face of hefty hep C competition from Gilead ($GILD) and AbbVie ($ABBV), can Daklinza profit from a set of niche uses? That's what maker Bristol-Myers Squibb ($BMY) is trying to find out. On Tuesday, the med nabbed the FDA's priority review tag for a trio of new indications in hard-to-treat patients. Regulators will examine the med for use with Gilead's Sovaldi in those who are coinfected with HIV-1, suffering from advanced cirrhosis, or experiencing recurrence of hep C after a liver transplant, the company said. More from FiercePharmaMarketing